



BC PharmaCare Newsletter

May 17, 2011 Edition 11-006

Published by the Pharmaceutical Services Division to provide information for British Columbia’s health care providers

QuickLinks

Reminder: Inducements for Prescriptions.....	1
New Reimbursement Limits for LCA Program Drugs —July 4, 2011	2
Special Services Fees.....	2
Benefits.....	3

REMINDER: INDUCEMENTS FOR PRESCRIPTIONS

The [PharmaCare Enrolment Agreement](#) disallows pharmacies from offering inducements to secure prescription orders, or in relation to the provision of a drug, medical supply, or service on the portion of the cost of that drug, supply or service paid for or reimbursed by the Province through PharmaCare.

As previously announced in PharmaCare Newsletters [10-014](#) and [10-015](#), PharmaCare deferred the enforcement of the requirements set out in the PharmaCare Enrolment Agreement with respect to **all** loyalty programs, including prescription transfer programs, until **July 4, 2011**. This deferral was intended to allow pharmacies time to decommission these programs and fulfill all their commitments to customers.

PharmaCare will enforce the requirements of the PharmaCare Enrolment Agreement with respect to inducements, for all pharmacies, once the deferral period has expired.

The use of PharmaNet is not intended as a substitute for professional judgment.
Information on PharmaNet is not exhaustive and cannot be relied upon as complete.

The absence of a warning about a drug or drug combination is not an indication that the drug or drug combination is safe, appropriate or effective in any given patient. Health care professionals should confirm information obtained from PharmaNet, and ensure no additional relevant information exists, before making patient care decisions.

NEW REIMBURSEMENT LIMITS FOR LCA PROGRAM DRUGS —JULY 4, 2011

Effective **July 4, 2011**, PharmaCare will change the reimbursement limits for applicable drugs in the Low Cost Alternative (LCA) categories as a result of the manufacturer pricing submission process for round two of the [Pharmacy Services Agreement](#) (Section 3.4).

Generic products deemed ineligible as a result of the reimbursement reduction process will be removed from the formulary, also effective July 4, 2011.

Maximum reimbursement limits and LCA prices will be published in the “Round 2 LCA Pricing Spreadsheet.”

In order to provide a transition period to help pharmacies with inventory adjustment, this spreadsheet will be available on or by June 4, 2011 at www.health.gov.bc.ca/pharmacare/lca/lca2011.html. The spreadsheet will also confirm which drugs within the LCA categories are eligible for PharmaCare reimbursement as of July 4, 2011.

Ongoing updates to the maximum reimbursement limits and LCA prices will continue to be published in the Low Cost Alternative (LCA) Data Files at www.health.gov.bc.ca/pharmacare/lca/lcabooklets.html.

Note: Manufacturers’ list prices for generic products deemed eligible for PharmaCare reimbursement from July 4, 2011 onwards should reflect the new reimbursement limits by June 4, 2011 (30 days before the new reimbursement limits take effect).

*On or by **June 4, 2011**, PharmaCare will publish a new LCA Spreadsheet listing reduced reimbursement limits for generic drugs.*

*Maximum reimbursement limits listed in the **Round 2 LCA Pricing Spreadsheet** will come into effect on **July 4, 2011**.*

SPECIAL SERVICES FEES

The number of Special Services fees that PharmaCare paid each month over the past year:

Apr 20111,654	Dec 2010..... 2,322	Aug 2010.....2,170
Mar 2011 1,556	Nov 2010 2,134	Jul 2010.....1,999
Feb 20111,262	Oct 2010 1,978	Jun 2010.....2,233
Jan 2011.....1,283	Sep 2010..... 2,211	May 20102,097

BENEFITS

Limited Coverage Drug Program Benefits

The following products are eligible benefits under the Limited Coverage Program—by Special Authority only—for Fair PharmaCare and Plans B, C and F. For the Special Authority criteria, please visit the [Special Authority Information](#) page available from the PharmaCare website at www.health.gov.bc.ca/pharmacare.

DIN	DRUG NAME	PLAN G	PLAN P
02322374	Abilify™ (aripiprazole) 2 mg	Yes	Yes
02322382	Abilify™ (aripiprazole) 5 mg	Yes	Yes
02322390	Abilify™ (aripiprazole) 10 mg	Yes	Yes
02322404	Abilify™ (aripiprazole) 15 mg	Yes	Yes
02322412	Abilify™ (aripiprazole) 20 mg	Yes	Yes
02322455	Abilify™ (aripiprazole) 30 mg	Yes	Yes

Non-Benefits

The following products have been reviewed and will not be added as benefits under PharmaCare.

DIN	DRUG NAME
02283395	Somatuline Autogel® (lanreotide acetate) 60 mg/0.2 ml
02283409	Somatuline Autogel® (lanreotide acetate) 90 mg/0.3 ml
02283417	Somatuline Autogel® (lanreotide acetate) 120 mg/0.5 ml
02273578	Uromax® (oxybutynin chloride) 10 mg controlled release tablet
02273586	Uromax® (oxybutynin chloride) 15 mg controlled release tablet
02280167	Asatab™ (acetylsalicylic acid) 80 mg chewable tablet
02103052	Alertonic® (pipradrol-vitamin B complex) elixir

De-Listing

At the request of the manufacturer, the following Regular Benefit product will be removed from the PharmaCare benefit list effective **June 17, 2011**.

DIN	DRUG NAME
02092832	MetroGel® (metronidazole) 0.75% topical gel